PRIMARY OBJECTIVE:~I. To assess the preliminary anti-tumor activity of erdafitinib in patients with recurrent or progressive IDH-WT glioma with FGFR-TACC gene fusion as measured by the best response at any time during treatment in terms of objective response rate (ORR).~SECONDARY OBJECTIVES:~I. To determine the safety and tolerability of erdafitinib in patients with recurrent or progressive IDH-WT glioma with FGFR-TACC gene fusion.~II. To assess the overall survival (OS) of erdafitinib in patients with recurrent or progressive IDH-WT glioma with FGFR-TACC gene fusion.~III. To assess the progression free survival (PFS) at 6 months of patient with IDH-WT glioma with FGFR-TACC gene fusion treated with erdafitinib.~OUTLINE: This is a dose-escalation study of erdafitinib followed by a dose-expansion study.~Patients receive erdafitinib orally (PO) on study. Patients also undergo magnetic resonance imaging (MRI), and collection of blood samples throughout the trial.~After study completion, patients are followed up every 3 months for 2 years.
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT) glioma with FGFR-TACC gene fusion that has come back (recurrent) or that is growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply. This may help keep cancer cells from growing and may kill them. Giving erdafitinib may help to slow the growth of or to shrink tumor cells in patients with recurrent or progressive IDH-wild type glioma with FGFR-TACC gene fusion.